CRx

Related by string. CRX * * CRX TSX.V provides . Honda CRX . Exchange CRX . Content Repository Extreme CRX . NASDAQ CRXL SWISS CRX . Honda CRX Si . Honda Civic CRX . SW CRX . CRX TSX Venture . CRX Si . CRX TSX.V *

Related by context. All words. (Click for frequent words.) 71 AEGR 69 NKTR 69 INCB# [001] 69 Traficet EN 69 PS# [001] 68 ARRY 68 VQD 68 CUDC 68 HZT 67 ISIS # 67 MAP# 67 Oral NKTR 67 IPL# 67 tanespimycin 67 Phase 2a clinical 67 PSN# [002] 66 PRTX 66 histone deacetylase HDAC inhibitor 66 Synavive 66 selective androgen receptor modulator 66 AEZS 66 elotuzumab 66 TELINTRA 66 Pimavanserin 66 CERE 66 LY# [002] 66 mertansine 66 KRN# 66 PRX # 66 Phenoptin 66 PDE4 inhibitor 65 rNAPc2 65 HspE7 65 tezampanel 65 alvimopan 65 CCX# 65 NGX# 65 MGCD# [001] 65 oral prodrug 65 JAK inhibitor 65 ganetespib 65 phase IIb clinical 65 phase IIa clinical 65 liposomal formulation 65 brivaracetam 65 Bezielle 65 MAGE A3 ASCI 65 AzaSite Plus 65 SCH # 64 Phase Ib study 64 LEVADEX 64 pan HDAC inhibitor 64 ELND# 64 zonisamide SR 64 LibiGel ® 64 CR# vcMMAE 64 Phase IIa trial 64 pomalidomide 64 initiate Phase 1b 64 MORAb 64 ZYBRESTAT 64 Triolex 64 lesinurad 64 Tesetaxel 64 Phase 2b study 64 PDX pralatrexate 64 telaprevir VX 64 MEK inhibitor 64 lexidronam injection 64 AAG geldanamycin analog 64 cannabinor 64 CoFactor 64 Tezampanel 64 JZP 64 mapatumumab 64 CORT # 64 MGCD# [002] 64 RG# ITMN 64 INGN 64 investigational humanized monoclonal antibody 64 Phase IIa trials 64 CB2 selective receptor agonist 64 ALTU 64 Phase 2a 64 Randomized Phase 64 GW# [003] 63 pertuzumab 63 R#/MEM # 63 PEG SN# 63 opioid induced bowel dysfunction 63 Phase Ib 63 BAY #-# 63 Varespladib 63 forodesine 63 thymalfasin 63 evaluating tivozanib 63 Phase 2b trial 63 non nucleoside inhibitor 63 orally administered inhibitor 63 Phase 2b clinical 63 PEG PAL 63 HCV SPRINT 63 Sym# 63 SRT# [003] 63 Golimumab 63 OXi# 63 phase IIb 63 PEG Interferon lambda 63 Aurexis 63 Phase 2a Clinical Trial 63 samarium Sm 63 favorable pharmacokinetic profile 63 otelixizumab 63 RGB # 63 bicifadine 63 HCV NS5B polymerase 63 tezampanel NGX# 63 Perifosine 63 Zenvia Phase III 63 Randomized Double blind 63 HGS ETR1 63 IMC A# 63 Ophena TM 63 orally bioavailable 63 Inhalation Solution 63 Androxal TM 63 Rebif ® 63 muraglitazar 63 ZOLINZA 63 ALKS 63 PXD# 63 virus HCV protease inhibitor 63 Avanafil 63 roflumilast 63 CCX# B 63 Zybrestat 62 CXA 62 metaglidasen 62 teriflunomide 62 GALNS 62 RSD# 62 sodium glucose cotransporter 62 Asentar 62 tasocitinib 62 TG# [003] 62 Bicifadine 62 phase IIa 62 Phase Ib clinical 62 visilizumab 62 OMNARIS HFA 62 investigational compound 62 QVA# 62 Phase 2b Study 62 BCX# 62 EVIZON 62 axitinib 62 HGS# 62 telcagepant 62 ALGRX 62 RhuDex ® 62 CEQ# 62 CA4P 62 Phase Ib clinical trials 62 diabetic neuropathic pain 62 Alocrest 62 phase IIb trial 62 Chrysalin 62 AEG# 62 HQK 62 Archexin 62 PrevOnco 62 Dapagliflozin 62 TELCYTA 62 davunetide intranasal AL 62 HCV protease inhibitor 62 Zenvia ™ 62 Pivotal Phase 62 HGS ETR2 62 urate lowering 62 reslizumab 62 Cannabinor 62 Phase 2a trial 62 LY# [003] 62 Phase 1b clinical 62 Panzem 62 elagolix 62 custirsen 62 ITMN 62 Mipomersen 62 MERLIN TIMI 62 Targretin 62 CIMZIA TM 62 GLYX 62 LEP ETU 62 placebo controlled Phase 62 Sapacitabine 62 pramlintide 62 6R BH4 62 IAP inhibitors 62 Elagolix 62 Phase IIb 62 Aflibercept 62 prasugrel CS 62 Aliskiren 62 Meets Primary Endpoint 62 SARMs 62 inhibitor RG# 62 QLT# 62 Phase #b/#a 62 obatoclax 62 apremilast 62 valopicitabine 62 INC# 62 Contrave# 62 ICA # 62 iCo 62 Phase IIb trials 62 active comparator 62 R roscovitine 62 AZILECT R 62 mipomersen 62 HDAC Inhibitor 62 JVRS 61 ATL# [001] 61 Hyphanox 61 oral ridaforolimus 61 dyskinesia PD LID 61 refractory gout 61 Pivotal Phase III 61 fosbretabulin 61 sorafenib tablets 61 GSK# [001] 61 CRLX# 61 PRT# 61 HuMax CD4 61 sargramostim 61 INT# [002] 61 TRX1 61 MT# MEDI 61 AQ4N 61 briakinumab 61 Panzem R 61 IDX# 61 mg BID 61 ocrelizumab 61 YONDELIS 61 Empatic 61 μg dose 61 HuMax EGFr 61 ularitide 61 dosing cohorts 61 Xyfid TM 61 Cethromycin 61 Tyrima 61 Dalbavancin 61 antidiabetic 61 systemic RNAi therapeutic 61 DDP# 61 Phase III Pivotal 61 polymerase inhibitor 61 MoxDuo 61 ostarine 61 alvespimycin 61 PSMA ADC 61 Zalbin 61 Factor VIIa 61 neratinib 61 ALN HPN 61 Lu AA# 61 Phase 2b 61 Radezolid 61 efficacy tolerability 61 GLPG# 61 desvenlafaxine 61 Vilazodone 61 Phase IIa clinical 61 iniparib 61 Ambrisentan 61 posaconazole 61 GSK# [002] 61 Phase IIb Trial 61 anti amnesic 61 torezolid phosphate 61 Viramidine 61 EXPAREL TM 61 XL# XL# XL# 61 Romidepsin 61 vidofludimus 61 LymphoStat B 61 Laquinimod 61 PF # [001] 61 Octreolin 61 Phase 1b 61 Phase IIb trial 61 BAL# [002] 61 huC# DM4 61 TLK# 61 Actilon 61 LE SN# 61 PEGylated Fab fragment 61 Anavex #-# 61 novel histone deacetylase 61 ADAGIO study 61 ponatinib 61 Panzem R NCD 61 TG MV 61 DAVANAT 61 ALVESCO HFA 61 MoxDuo TM IR 61 FOLOTYN ® 61 Icatibant 61 oral FTY# 61 Azedra ™ 61 CIMZIA TM certolizumab pegol 61 Virulizin ® 61 Phase 2b Clinical Trial 61 Phase 1b trial 61 docetaxel Taxotere R 61 INKP 61 preclinical efficacy 61 peripherally acting 61 controlled multicenter Phase 61 cobiprostone 60 sorafenib Nexavar 60 Azixa 60 PLK1 SNALP 60 plasma kallikrein inhibitor 60 ACAPODENE 60 dacetuzumab 60 Apixaban 60 ALN PCS 60 iSONEP 60 HCV RESPOND 2 60 sapacitabine 60 topical gel formulation 60 Pafuramidine 60 Corlux 60 JAK1 60 pharmacokinetic PK profile 60 riociguat 60 VA# [002] 60 Amrubicin 60 Synavive ™ 60 mg dose 60 Phase Ib Clinical Trial 60 Maribavir 60 Carfilzomib 60 CD3 monoclonal antibody 60 Prednisporin 60 Exelixis compounds 60 ISENTRESS 60 RDEA# 60 SNRI 60 talactoferrin 60 RVX 60 Xanafide 60 OncoVEX GM CSF 60 nitazoxanide 60 metformin sulfonylurea 60 candesartan cilexetil 60 TBC# 60 Initiated Phase 60 immunomodulating 60 enzastaurin 60 Cytogen marketed 60 menadione 60 Microplasmin 60 Aplidin R 60 palifosfamide Zymafos TM 60 vicriviroc 60 Allovectin 7 R 60 ADXS# 60 TYKERB 60 vascular disrupting agent 60 novel VDA molecule 60 COU AA 60 targeted radiotherapeutic 60 Cardio Vascu Grow 60 budesonide foam 60 long acting muscarinic 60 Phase IIb clinical 60 phase 2a 60 TKM ApoB 60 alagebrium 60 MNTX 60 eltrombopag 60 Guanilib 60 novel topoisomerase 60 integrin inhibitor 60 aflibercept 60 adipiplon 60 ALN TTR 60 Ozarelix 60 hour bronchodilation 60 4SC 60 IL# PE#QQR 60 INCB# [002] 60 Debio 60 orally administered 60 prodrug 60 ANG# 60 pharmacodynamic properties 60 CYT# 60 Civacir 60 mg RDEA# 60 TPI ASM8 60 ALN TTR# 60 mixed dyslipidemia 60 mg TID 60 HCV protease inhibitors 60 Talabostat 60 safinamide 60 EZN 60 Daclizumab 60 zileuton 60 octreotide acetate 60 pharmacokinetic PK study 60 PCK# 60 FASLODEX 60 ProSavin 60 Cimzia ® certolizumab pegol 60 tolvaptan 60 EndoTAG TM -1 60 tesmilifene 60 GABITRIL 60 Dyloject TM 60 APTIVUS r 60 HuMax CD# 60 ACTEMRA TM 60 Treanda 60 investigational compounds 60 AVE# 60 BRAF inhibitor 60 Xeloda ® 60 APD# 60 Naproxcinod 60 Zemiva ™ 60 JAK2 inhibitor 60 LEVADEX TM 60 HuLuc# 60 omacetaxine mepesuccinate 60 Lacosamide 60 BRIM2 60 Hsp# inhibitor 60 Parkinson disease levodopa induced 60 CANCIDAS 60 Genz # 60 metastatic hormone refractory 60 preclinically 60 Excellagen 60 XL# XL# 60 Phase 1a clinical 60 NVA# 60 MoxDuo IR 60 belinostat 60 tecarfarin 60 darapladib 60 CCR5 antagonist 60 RhuDex 60 Initiate Phase 60 dextromethorphan quinidine 60 Alfimeprase 60 FM VP4 60 squalamine 60 celgosivir 60 Pertuzumab 60 Multimeric 60 Omacetaxine 60 Tarceva TM 60 AZD# 60 Milnacipran 60 beta 1a 60 Squalamine 60 TREANDA 60 Levetiracetam 60 Azedra 60 QNEXA 60 Bortezomib 60 multicenter Phase II 60 radiation sensitizer 60 NXL# 60 Zelrix 60 tolerability profile 60 multi kinase inhibitor 60 ThGRF 60 vascular disrupting agents 59 Menerba 59 Ecallantide 59 Antiviral Activity 59 ongoing Phase 1b 59 Tolerability 59 Iluvien ® 59 phase Ib 59 Elocalcitol 59 castrate resistant prostate cancer 59 anidulafungin 59 Ramoplanin 59 MTP inhibitor 59 novel prodrug 59 INCB# [003] 59 tasimelteon 59 REG1 59 AVONEX ® 59 zolmitriptan 59 OMS#HP 59 interferon gamma 1b 59 KSP inhibitor 59 lintuzumab SGN 59 intranasal formulation 59 SAR# [002] 59 phase III isavuconazole 59 RG# [001] 59 OMS# 59 decitabine 59 Ticagrelor 59 VLTS 59 nab paclitaxel 59 Epothilone D 59 VAPRISOL 59 ceftazidime 59 GRN#L 59 Fx #A 59 lasofoxifene 59 resolvin 59 antithrombotic 59 XmAb# 59 investigational protease inhibitor 59 Palifosfamide 59 Diabetic Macular Edema 59 Glufosfamide 59 bosutinib 59 phase IIb study 59 non nucleoside HCV 59 alemtuzumab Campath 59 Phase IIB 59 Tasimelteon 59 sulodexide 59 Zenvia TM 59 rasagiline tablets 59 CORLUX 59 proteasome inhibitor 59 regorafenib 59 DermaVir Patch 59 Locteron 59 incyclinide 59 fenofibric acid 59 ELND# AZD 59 SERMs 59 SELZENTRY 59 BZL# 59 Darusentan 59 metastatic castration resistant 59 Nanobody 59 targeting CD# 59 injectable formulation 59 midstage clinical 59 ADP receptor antagonist 59 EQUIP OB 59 AeroLEF TM 59 LibiGel Phase III 59 Linaclotide 59 DU #b 59 AZILECT ® 59 Iloperidone 59 ENMD # 59 Imprime PGG 59 SinuNase TM 59 Chemophase 59 Capesaris 59 Tekturna HCT 59 investigational drug 59 Alzhemed TM 59 mGluR5 NAM 59 AP# [003] 59 canagliflozin 59 APEX PD 59 SinuNase 59 ZYBRESTAT TM 59 ATL/TV# 59 lomitapide 59 TASKi2 59 pralatrexate 59 pramlintide metreleptin combination 59 Dasatinib 59 Phase IIb Clinical Trial 59 Tß4 59 HCV protease 59 CCR9 antagonist 59 Eltrombopag 59 MEK inhibitors 59 administered subcutaneously 59 Amplimexon 59 PNP inhibitor 59 orally inhaled migraine 59 TriRima 59 PREZISTA rtv 59 clevidipine 59 Peginterferon 59 SILENOR 59 BENICAR HCT 59 Excellarate TM 59 Cetrorelix 59 Serdaxin ® 59 XP# XP# 59 daclizumab 59 Phase 2b Trial 59 atacicept 59 MYCAMINE 59 idraparinux 59 Anturol ® 59 insulin sensitizers 59 selective androgen receptor modulators 59 bevirimat 59 Omacetaxine mepesuccinate 59 CYT# QbG# 59 BMN 59 octreotide implant 59 baminercept 59 RELOVAIR ™ 59 Antiangiogenic 59 cangrelor 59 Zoraxel 59 INS# [001] 59 milnacipran 59 Welchol 59 Intervention Effectiveness 59 dasatinib Sprycel ® 59 ILUVIEN ® 59 ulimorelin 59 IAP inhibitor 59 humanized anti 59 Safinamide 59 Silodosin 59 colesevelam HCl 59 atrasentan 59 ocular formulation 59 TMC# [002] 59 NUVIGIL 59 mTOR inhibitors 59 Nasulin 59 Perforomist ™ Inhalation Solution 59 Phase Ib II 59 tiapamil 59 pharmacodynamic effects 59 CYC# 59 nucleotide analog 59 topical antifungal 59 CIMZIA ™ 59 Panzem NCD 59 MKC# MKC# PP 59 aprepitant 59 lacosamide 59 urocortin 2 59 Phase IIa 59 rilonacept 59 NP2 Enkephalin 59 Otelixizumab 59 NB S# 59 seliciclib 59 Saxagliptin 59 Ketotransdel 59 relapsed refractory multiple myeloma 59 PREZISTA r 59 Phase Ia 59 treatment naïve genotype 59 IRX 2 59 SYN# 59 docetaxel Taxotere ® 59 entinostat 59 MEND CABG 59 inhaled formulation 59 CD# antibody [001] 59 Cethrin 59 deforolimus 59 BRIM3 59 BEMA Buprenorphine 59 Seliciclib 59 Fibrillex TM 59 compound ITMN 59 generation antisense 59 bifeprunox 59 PHX# 59 Rotigotine 59 pegylated 59 ATL# [002] 59 ATHX 59 dose cohort 59 Perforomist TM Inhalation Solution 59 Dacogen injection 59 radiolabeled monoclonal antibody 59 subcutaneously administered 58 mGluR5 negative 58 Phase 1b clinical trials 58 Phase #b/#a clinical 58 BEMA TM Fentanyl 58 Vitaxin 58 perampanel 58 Personalized Immunotherapy 58 IMA# 58 PSN# [001] 58 vinorelbine 58 Omnitarg 58 Telaprevir VX 58 ISTODAX 58 EFAPROXYN 58 Stedivaze 58 oral picoplatin 58 Aurora Kinase 58 zalutumumab 58 pegylated interferons 58 Anturol TM 58 methylnaltrexone 58 histone deacetylase inhibitor 58 Azedra TM 58 Serdaxin 58 LAF# 58 TOCOSOL Paclitaxel 58 bortezomib Velcade 58 TRIOLEX HE# APOPTONE HE# 58 blinded randomized placebo controlled 58 pivotal Phase III 58 FOLPI 58 comparator arm 58 Vandetanib 58 OMNARIS Nasal Spray 58 gemcitabine Gemzar 58 transcriptase inhibitor 58 tocilizumab 58 Solorel TM 58 Ixempra 58 Cloretazine ® 58 CTAP# Capsules 58 latrepirdine 58 tolerability 58 Vaprisol 58 Trexima 58 tarenflurbil 58 Lialda 58 lead Aganocide compound 58 cilengitide 58 intravenously administered 58 mg/m2 dose 58 Symadex 58 Dual Opioid 58 CEROVIVE NXY 58 ELACYT 58 diarrhea predominant irritable 58 plus prednisone 58 Solzira 58 DOS# 58 EOquin TM 58 #mg BID [001] 58 bendamustine 58 DCCR 58 mg q#h 58 TRO# 58 Phase #b/#a trial 58 Phase IIb clinical trials 58 IMC #B 58 orally dosed 58 methionine aminopeptidase 58 antifibrotic 58 Navelbine 58 2 methoxyestradiol 58 trastuzumab Herceptin R 58 randomized Phase IIb 58 FTY# 58 Elitek 58 somatostatin analogue 58 novel immunomodulatory 58 Ostarine 58 Ridaforolimus 58 HCV polymerase inhibitors 58 Tanespimycin 58 PROVENGE sipuleucel T 58 Phase 1a 58 Xinlay 58 novel oral anticoagulant 58 pharmacokinetic PK 58 HSP# inhibitor 58 Lubiprostone 58 teduglutide 58 FOLFOX6 chemotherapy regimen 58 Spiegelmer ® 58 Bavituximab 58 DexaSite 58 Phase IIIb clinical 58 Sulonex 58 irbesartan 58 metastatic HRPC 58 Leukine 58 Atrasentan 58 NATRECOR R 58 oral rivaroxaban 58 R#/MEM 58 highly selective inhibitor 58 Tolvaptan 58 darinaparsin ZIO 58 Indaflex TM 58 Phase III Clinical Trial 58 volociximab 58 mu opioid receptor antagonist 58 Ustekinumab 58 GAMMAGARD 58 Neurodex 58 preclinical studies 58 CDP# 58 aleglitazar 58 prucalopride 58 liposome injection 58 Altropane 58 COPEGUS 58 uric acid lowering 58 temsirolimus 58 TACI Ig 58 AXIRON ™ 58 Ocrelizumab 58 thiazolidinedione 58 Amigal 58 Rigel R# 58 preclinical pharmacokinetic 58 Excellarate 58 TriLipix 58 ascending dose 58 randomized discontinuation trial 58 Boceprevir 58 CYT# potent vascular disrupting 58 CD# CEA 58 valopicitabine NM# 58 Tiotropium 58 Pazopanib 58 treatment naive genotype 58 interferon alfa 58 ORENCIA R 58 MEK Inhibitor 58 dose escalation Phase 58 febuxostat 58 analgesic efficacy 58 MKC# 58 Phase #/#a 58 L BLP# 58 ZYBRESTAT fosbretabulin 58 Pharmacokinetics PK 58 paclitaxel Taxol ® 58 Ceflatonin R 58 ADX# 58 Zolinza 58 Cyclooxygenase Inhibiting Nitric Oxide 58 PORxin TM 58 oral antifungal 58 pradefovir 58 dose cohorts 58 hylan GF 58 galiximab 58 HCD# [002] 58 cyclophilin inhibitor 58 TRIOLEX 58 Marqibo 58 BNC# 58 TREDAPTIVE 58 teriparatide 58 partial agonist 58 systemic absorption 58 Cleviprex TM clevidipine 58 investigational oral 58 hyperphenylalaninemia HPA due 58 TÎ ² 4 58 Nuvion 58 delta isoform 58 protein kinase inhibitor 58 HMG CoA reductase inhibitor 58 NNR Therapeutics 58 EGS# 58 Levoleucovorin 58 Atiprimod 58 IMiDs 58 Anticalin R 58 desvenlafaxine succinate 58 5 HT6 receptor 58 Solazed TM 58 MYDICAR 58 Myocet 58 selective A2A adenosine receptor 58 CB1 antagonists 58 REG2 58 Cinquil 58 vilazodone 58 class mGluR5 inhibitor 58 Pivotal Trial 58 ruxolitinib 58 microplasmin 58 acyclovir Lauriad R 58 APTIVUS 58 romidepsin 58 lumiliximab 58 selective antagonist 58 Aryplase 58 midstage studies 58 mg QD 58 bortezomib Velcade R 58 SAR# [004] 58 Bremelanotide 58 Irinotecan 58 CINTREDEKIN BESUDOTOX 58 Lenocta 58 placebo controlled studies 58 Phase 2b clinical trials 58 Tβ4 58 delafloxacin 58 SinuNase ™ 58 Protelos 58 anticancer compound 58 Phase III placebo controlled 58 relapsed multiple myeloma 58 Neulasta ® 58 alemtuzumab MS 58 bafetinib 58 ONTARGET 58 Cloretazine R VNP#M 58 dermal patch 58 Starlix 58 Pioglitazone 58 antisense drug 58 VISICOL R 58 vorinostat 58 Ceflatonin 58 Aclidinium 58 Diamyd ® 58 Hsp# Inhibitor 58 standard chemotherapy regimen 58 anti CD# antibodies 58 PROMACTA 58 IV APAP 58 CG# [003] 58 MEVACOR 58 Apoptone 58 varespladib 58 ONCONASE R 58 GFT# 58 Entereg R 58 Ereska 58 RSD# oral 58 5 HT3 antagonist 58 Resten NG 58 LATUDA 58 RSR# 58 aclidinium 58 Cethrin R 58 E1 INT TM 58 Phase III clinical 58 pan histone deacetylase 58 alfa 2a 58 sunitinib malate 58 PDE4 inhibitors 58 MPS IVA 58 RLY# 58 investigational hepatitis C 58 allosteric modulator NAM 58 Kahalalide F 58 prokinetic agent 58 INVEGA ® 58 nitric oxide donating 58 Trial Evaluating 58 Eloxatin R 57 salmeterol fluticasone 57 placebo controlled clinical 57 DB# [003] 57 pharmacodynamic profile 57 TKB# 57 dose escalation trial 57 topical NSAID 57 TH# [003] 57 eprotirome 57 arzoxifene 57 trodusquemine 57 EcoNail 57 brostallicin 57 Elvitegravir 57 benazepril 57 PA# [002] 57 generation antisense inhibitor 57 ANYARA 57 Trofex 57 aplindore 57 davalintide 57 CCR5 mAb 57 XL# XL# XL# XL# 57 maraviroc 57 rFIXFc 57 bardoxolone methyl 57 tolevamer 57 phase IIIb 57 mycophenolate mofetil 57 AGHD 57 Plicera 57 DPP4 inhibitor 57 Fibrin Pad 57 double blinded placebo 57 immunomodulator

Back to home page